@article { author = {}, title = {Treatment Efficacy and Prognostic Factors for Huge HCC Based on Barcelona Clinic Liver Cancer Staging}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {15}, number = {20}, pages = {8823-8828}, year = {2014}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {Objective: To explore the most appropriate treatment for patients with hepatocellular cancer (HCC) >10 cmby using the Barcelona Clinic Liver Cancer (BCLC) classification. Materials and Methods: A total of 124 HCCpatients undergoing surgery were selected. Disease-free survival (DFS), overall survival (OS) and prognosticfactors were respectively assessed. Results: This study showed that the cumulative 1-, 3-, 5-year survival rateswere 79.7%, 59.8% and 41.6% in BCLC-A patients, 76.2%, 9.5% and 0% in BCLC-B patients and 44.9%, 0%and 0% in BCLC-C patients, respectively. The 1-, 3-, 5-year DFS rates were 49%, 24.5% and 9.1% in BCLC-Apatients, 7.5%, 0% and 0% in BCLC-B patients, respectively. No BCLC-C patients survived 1 year after surgery.Multivariate analysis indicated that hepatitis B surface antigen (HBsAg), vascular invasion, intra-hepaticmetastasis, curative resection, tumor rupture and pathologic differentiation were independent prognostic factors.Conclusions: Surgery is effective and safe for patients with HCC >10 cm with sufficient hepatic reserve.}, keywords = {Barcelona clinic liver cancer staging,huge hepatocellular carcinoma,hepatectomy,Efficacy}, url = {https://journal.waocp.org/article_30002.html}, eprint = {https://journal.waocp.org/article_30002_ee685be1dcec515364eee873eeff3c07.pdf} }